Prescreening for COVID-19 in patients receiving cancer treatment using a patient-reported outcome platform

ESMO Open. 2020 Jun;5(3):e000817. doi: 10.1136/esmoopen-2020-000817.

¹ Department of Medical Oncology, MOCA, University Hospital Antwerp (UZA), Antwerp, Belgium; Department of Molecular Imaging, Pathology, Radiotherapy & Oncology (MIPRO), Center for Oncological Research (CORE), Antwerp University, Antwerp, Belgium. Electronic address: marc.peeters@uza.be.
² Department of Molecular Imaging, Pathology, Radiotherapy & Oncology (MIPRO), Center for Oncological Research (CORE), Antwerp University, Antwerp, Belgium; Unit of Gynecologic Oncology, Department of Obstetrics & Gynecology, MOCA, University Hospital Antwerp (UZA), Antwerp, Belgium.
³ Unit of Gynecologic Oncology, Department of Obstetrics & Gynecology, MOCA, University Hospital Antwerp (UZA), Antwerp, Belgium.
⁴ Department of Molecular Imaging, Pathology, Radiotherapy & Oncology (MIPRO), Center for Oncological Research (CORE), Antwerp University, Antwerp, Belgium; Department of Medical Oncology, AZ Maria Middelares VZW, Gent, Belgium.
⁵ Department of Medical Oncology, AZ Maria Middelares VZW, Gent, Belgium.
⁶ Remedus Bvba, Aartselaar, Belgium.
⁷ Unit of Thoracic Oncology, MOCA, University Hospital Antwerp (UZA), Antwerp, Belgium.
⁸ Department of Medical Oncology, MOCA, University Hospital Antwerp (UZA), Antwerp, Belgium; Department of Molecular Imaging, Pathology, Radiotherapy & Oncology (MIPRO), Center for Oncological Research (CORE), Antwerp University, Antwerp, Belgium.

No abstract available

Keywords: COVID-19; cancer; prescreening; telemonitoring.

Publication types